Former X CEO Linda Yaccarino takes eMed top job
"Yaccarino's hiring is a game changing moment in eMed's mission to make safe, effective, and sustainable chronic care accessible directly through an all-in-one, digital-first experience," eMed said in a press release. "Her unparalleled experience in leading paradigm shifting transformations will bring a new dimension to the company."
Yaccarino had stepped down from her post at X in July after a two-year stint without an explanation, but her resignation came a day after the X chatbot Grok had gone on an anti-Semitic tirade.
EMed is currently at work on a population health management platform for the GLP-1 weight loss and diabetes drugs. Goldman Sachsresearchers have estimated that about 15 million adults in the United States alone may be treated with anti-obesity medications, or AOMs by 2030, and that the industry could reach $100 billion in annual revenue by that year.
"The healthcare industry has been disrupted by technology, but not yet completely transformed by it," Yaccarino said in the release. "There is an opportunity to combine technology, lifestyle, and data in a new powerful way through the digital channels that impact consumers directly in ways that have never been done before."
Copyright 2025 UPI News Corporation. All Rights Reserved.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
13 minutes ago
- Business Wire
Backblaze Announces $10 Million Share Repurchase Program
SAN MATEO, Calif.--(BUSINESS WIRE)--Backblaze, Inc. (Nasdaq: BLZE), the cloud storage innovator providing a modern alternative to traditional cloud providers, today announced that its Board of Directors authorized a share repurchase program to purchase up to $10 million of shares of its common stock through August 1, 2026. With the company on track to turn Adjusted Free Cash Flow positive in Q4 of 2025, using cash from employee exercised stock options and purchases under the Employee Stock Purchase Plan to buy back common stock in the market will help preserve the cash balance of the company, while reducing equity dilution. 'With our progress solidifying our Balance Sheet, and our acceleration of our B2 Cloud Storage growth, we are now expanding our focus to manage our equity dilution from stock compensation. When looking at our metrics, we are excited about the pace of improvement across key pillars to transform our financial model, including liquidity, free cash flows and revenue growth acceleration,' said Marc Suidan, Chief Financial Officer. The program will be funded through the cash proceeds from stock options exercised by employees and employee purchases under the Employee Stock Purchase Plan, which is intended to be cash neutral to the company. The shares may be repurchased from time to time in open market transactions, privately negotiated transactions, or by other means, including automatic purchase plans pursuant to Rule 10b5-1, in accordance with applicable securities laws. The timing, number of shares repurchased, and prices paid for the shares under this program will be generally determined by management based on its evaluation of general business and market conditions as well as corporate and regulatory limitations, prevailing stock prices, and other considerations. The Share Repurchase Program may be suspended, modified, or discontinued at any time and does not obligate the Company to acquire any particular amount of common stock. About Backblaze Backblaze is the cloud storage innovator delivering a modern alternative to traditional cloud providers. We offer high-performance, secure cloud object storage that customers use to develop applications, manage media, secure backups, build AI workflows, protect from ransomware, and more. Backblaze helps businesses break free from the walled gardens that traditional providers lock customers into, enabling them to use their data in open cloud workflows with the providers they prefer at a fraction of the cost. Headquartered in San Mateo, CA, Backblaze (NASDAQ: BLZE) was founded in 2007 and serves over 500,000 customers in 175 countries around the world. For more information, please go to
CNBC
an hour ago
- CNBC
Eli Lilly's obesity pill led to more than 12% weight loss in closely watched late-stage trial, paving way for approval
Eli Lilly on Thursday said the highest dose of its daily obesity pill helped patients lose more than 12% of their body weight, or roughly 27 pounds, at 72 weeks in a late-stage trial, paving way for its entrance into the market. Some doctors said the results appear to be comparable to, if not slightly lower, the level of weight loss seen with Novo Nordisk's blockbuster weekly GLP-1 injection for obesity, Wegovy. The data comes under what some Wall Street analysts were expecting for Eli Lilly's oral GLP-1, with hopes for weight loss of around 15%. Some doctors also made note of the number of patients on the highest dose of the pill who discontinued treatment due to side effects or any other reason in the trial. Still, other doctors lauded the results and the potential of the pill to reach new patients, such as those who are afraid of needles. "This is a strong and promising result for an oral agent," said Dr. Jaime Almandoz, medical director of the Weight Wellness Program at UT Southwestern Medical Center, calling the weight loss "a significant and clinically meaningful outcome." "Injectables have set a high bar, but this study reinforces the potential for an oral GLP-1 to be transformative in obesity care, particularly for patients who are hesitant to start or maintain injectable therapies," he continued. Dr. Mihail "Misha" Zilbermint, director of Endocrine Hospitalists at the Johns Hopkins Community Physicians, said he believes the pill "has the potential to be a game changer, as long as people can tolerate the side effects." The trial results are among the pharmaceutical industry's most closely watched studies of the year, and follow positive data in April from a phase three trial examining the experimental pill in diabetes patients. They bring Eli Lilly's pill, orforglipron, one step closer to becoming the first new, needle-free alternative in the booming market for weight loss and diabetes drugs called GLP-1s. Eli Lilly expects to submit the data to regulators by the end of the year, with plans to launch the pill in 2026, Ken Custer, president of Lilly Cardiometabolic Health, said in an interview. That launch could fundamentally shift the space, helping more patients access the treatments and alleviating the supply shortfalls of existing injections. The more convenient and easier-to-manufacturer pill could also help Eli Lilly solidify its dominance in the growing segment as other drugmakers, including its main rival Novo Nordisk, race to bring weight loss pills to market. Custer said there are roughly 8 million patients on injectable obesity and diabetes drugs, but likely around 170 million who could benefit from the medicines. "In order to meet that demand, we're going to need other options, including oral small molecules like orforglipron, which use different means of production and also don't need as sophisticated of a supply chain to distribute it to patients," he said. Dr. Amy Sheer, professor of medicine and program director of the Obesity Medicine Fellowship at University of Florida, said she hopes the pill will be less expensive than existing injections, which are costly largely due to the devices they come in. She said lower prices could help eliminate barriers to access for patients, potentially making insurers more willing to cover the drug. Many insurers still don't cover GLP-1s for obesity. Wegovy and other drugs have list prices of roughly $1,000 before insurance. The highest dose of Eli Lilly's pill helped more than 59% of patients lose at least 10% of their body weight and more than 39% of patients lose at least 15% of their weight, according to the trial results. Almandoz said the proportion of people who achieved "greater magnitudes" of weight loss was "very impressive for an oral agent," adding that many people "often overlook the proportion of people achieving these high weight loss categories" and typically focus closely on the average weight loss Orforglipron also helped lessen cardiovascular risk factors. But data on how well some patients tolerated the pill in the trial came under some analysts' estimates. About 10.3% of patients who took the highest dose of the pill — 36 milligrams — discontinued treatment due to side effects, compared with around 2.6% of those who took placebo. Those side effects were mainly gastrointestinal, such as nausea and vomiting, and mild to moderate in severity. An estimated 24% of those who took the highest dose experienced vomiting, while 33.7% and 23.1% had nausea and diarrhea, respectively. Ahead of the data, BMO Capital Markets analyst Evan Seigerman said he expected less than 10% of patients on the highest dose of the pill to discontinue treatment due to side effects and lower rates of vomiting, nausea and diarrhea. More patients stopped taking the pill due to side effects compared with existing GLP-1s on the market, said Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital. The discontinuation rates due to side effects in late-stage trials on Wegovy and Eli Lilly's weekly obesity injection Zepbound are around 7% or less. She noted that almost a quarter of patients on the highest dose of the pill discontinued treatment for any reason, cautioning that the enthusiasm for orforglipron should be tempered "because we get all this excitement, and then the pill comes out, and then nobody can take it." It's unclear why, apart from side effects, those patients discontinued the pill. But University of Florida's Sheer said she doesn't believe the discontinuation rates or side effects will be a deciding factor for physicians when prescribing the pill. She believes an oral option could actually make more physicians more comfortable prescribing a GLP-1 to patients. Some physicians are currently hesitant to prescribe injections because they "may not know how to tell patients how to use them," Sheer added. Almandoz said prescribing decisions are going to depend on the patient's specific needs and preferences, as well as access and affordability. An injectable GLP-1 may be the preferred option for patients whose priority is a greater level of weight loss or those who have significant cardiometabolic complications, or health issues that arise from cardiovascular diseases and metabolic disorders. But an oral GLP-1 could be the best fit for those who "prioritize simplicity or convenience or have these logistical challenges with injections," he said. The detailed results from the trial will be presented in September at a European medical meeting and published in a peer-reviewed journal. More phase three trial results on the pill will be shared later this year, including from a study on adults who have obesity or are overweight and have Type 2 diabetes. Wegovy, Eli Lilly's pill, orforglipron and Novo Nordisk's diabetes pill Rybelsus all work by targeting a gut hormone called GLP-1 to promote weight loss and regulate blood sugar. But unlike those other medications, Eli Lilly's pill is not a peptide medication. That means it is absorbed more easily in the body and doesn't require dietary restrictions like Rybelsus does. Eli Lilly is currently about three years ahead of other drugmakers developing pills, including Pfizer, AstraZeneca, Roche, Structure Therapeutics and Viking Therapeutics, Guggenheim analyst Seamus Fernandez previously CNBC. Some analysts expect the market for GLP-1s to be worth more than $150 billion annually by the early 2030s. Oral GLP-1s could grow to be worth $50 billion of that total, Fernandez said.
Time Magazine
an hour ago
- Time Magazine
Eli Lilly Says Its New Weight-Loss Pill Is Highly Effective
In eagerly awaited results from a new study, the pharmaceutical company Eli Lilly reports that a pill its scientists developed causes people who are overweight or obese, but not diabetic, to lose significant amounts of weight. The drug, called orforglipron, differs from Lilly's injectable drug, tirzepatide (which is approved as Mounjaro to treat diabetes and as Zepbound to treat obesity and some forms of obstructive sleep apnea). While tirzepatide targets two hormones, GLP-1 and GIP, orforglipron just targets GLP-1. Lilly and other companies that make similar medicines have been racing to create oral weight-loss drugs, since weekly injections are not always appealing to patients. The trial included more than 3,100 overweight or obese adults who had an obesity-related medical problem but not diabetes. Those taking the pill daily for almost a year and a half lost 12% of their body weight on average, or 27 pounds. People taking a placebo lost just over two pounds. The findings have not yet been published in a peer-reviewed journal but will be presented in September at the annual meeting of the European Association for the Study of Diabetes. Based on the results, Lilly says it plans to file for approval of orforglipron from the U.S. Food and Drug Administration to treat obesity by the end of the year. If approved, Lilly says, it will be able to provide the pills by next year. The company is waiting for final results from a similar study of weight loss in people with diabetes; early results released in April indicate that the drug helped people with diabetes lower their blood sugar. 'The results we got were as good as we can possibly achieve with an oral small molecule GLP-1," says Dr. Dan Skovronsky, Lilly's chief scientific officer. 'The safety, tolerability, and efficacy were all in line with what we achieved with the injectable drug, yet now delivered in an easy-to-use, once-a-day pill.' Read More: The Health Risks and Benefits of Weight-Loss Drugs Among people in the study who took the drug, risk factors for heart disease such as LDL cholesterol, triglycerides, blood pressure, and a marker of inflammation also dropped, Skovronsky notes. That supports earlier data finding that GLP-1 drugs can lower the risk of heart disease as well. As with the injectable form, people taking the pills had to gradually increase their dose before reaching the maximum dose, mainly to minimize the side effects of gastrointestinal distress. In the study, people started out at 6 mg, then increased to 12 mg four weeks later, then to the maintenance dose of 36 mg four weeks after that. Orforglipron's side effect profile was similar to that of the injectable drugs, which is reassuring, says Skovronsky. 'There were two things I worried about,' he says. 'One, when you take something orally, you are exposing the stomach and intestines to a higher concentration of the drug. If that's where the side effects are caused, then [the oral] form could make them worse. But it wasn't the case at all.' It also wasn't clear what would happen if people in the study missed doses, since it's sometimes challenging to take a pill every day. Because the dose is carefully titrated up, Skovronsky said it wasn't known if people who missed pills for a few days would lose the tolerance they had built up to the side effects and have to restart their dosing schedule. 'What we found was that the side effects were similar to the injections, even though people missed the dose every once in a while,' he says. Read More: Is Ozempic the New Anti-Inflammatory Wonder Drug? Novo Nordisk, a competitor that makes Ozempic for treating diabetes and Wegovy for weight management, also has an oral form of its active ingredient, semaglutide, that is already approved to treat diabetes. The company has applied for approval to treat obesity in people without diabetes and expects a decision by the end of the year. If orforglipron is approved, it could increase access to GLP-1 medications in the U.S. and around the world. The oral drug is cheaper than the injectable, since it does not require a sterile injectable pen. Some people are also reluctant to inject themselves weekly, so taking the medication by mouth would be a welcome option. As more doctors and patients figure out the best way to use GLP-1 drugs to manage weight, a pill could either kickstart weight loss or become part of a long-term maintenance program for people who have hit their weight-loss goal. 'This can enable us to go earlier in the disease course, because people sometimes hold off on the injections until the disease—in this case, obesity—is more severe,' says Skovronsky. 'We want to treat obesity at its earliest stages, and this provides a good opportunity to do that.' Skovronsky says Lilly is also studying weight-maintenance approaches with orforglipron.
